中國新經濟投資(00080.HK)建議“2供1”供股
格隆匯1月7日丨中國新經濟投資(00080.HK)公吿,董事會建議“2供1”進行供股,以透過供股向合資格股東發行最多4.54億股供股股份的方式籌集所得款項總額最多約8170萬港元(扣除開支前)(假設於記錄日期或之前所有未行使購股權獲悉數行使及並無進一步發行或購回股份)以及以透過供股向合資格股東發行4.32億股供股股份的方式籌集所得款項總額約7780萬港元(扣除開支前)(假設於記錄日期或之前概無未行使購股權獲行使及並無進一步發行或購回股份),認購價為每股供股股份0.18港元,認購價較股份於最後交易日在聯交所收市價0.25港元折讓約28.0%。
供股的估計所得款項淨額(倘獲悉數認購,於扣除有關供股的所有必要開支後)估計約為7400萬港元。董事經考慮到公司現金結餘及供股所得款項淨額後確認,供股完成後,公司將擁有滿足未來12個月的充足營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.